CRVO

CervoMed Inc. CRVO

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,923 of 2,925

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$0

Quarter to Jun 30

Net income

$-6.57M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$5.42M total
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CRVO

Earnings Per Share

13fpro.ai/company/CRVO

Loading ratio trend…

CRVO key financials by period

Reported revenue, net income and operating margin by fiscal year, from CervoMed Inc.'s annual filings on SEC EDGAR.

CervoMed Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$4.0M$-27.0M—
FY 2024$9.7M$-16.3M-187.2%
FY 2023$7.1M$-2.2M-109.3%
FY 2013$71.7K$-2.5M—
FY 2012$374.5K$-6.9M—
FY 2011$570.5K$-22.6M—
Source: CRVO filings on SEC EDGAR →

CRVO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About CervoMed Inc. (CRVO): stock profile, AI score and financials

CervoMed Inc. (CRVO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRVO at 4.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,923 of 2,925 stocks — the bottom half of the AI-ranked universe. Top institutional holders of CRVO by reported 13-F value include Woodline Partners, VANGUARD CAPITAL MANAGEMENT, SABBY MANAGEMENT, based on the most recent SEC filings. CRVO trades on the Nasdaq exchange and files with the SEC under CIK 1053691. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRVO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CervoMed Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1053691 →